Literature DB >> 8310798

N-methyl-D-aspartate receptor antagonist MK-801 induced circling behavior in rats with unilateral striatal ischemic lesions or nigral 6-hydroxydopamine lesions.

S Goto1, K Korematsu, N Inoue, K Yamada, T Oyama, S Nagahiro, Y Ushio.   

Abstract

The present study shows that systemic administration of the selective, non-competitive N-methyl-D-aspartate antagonist MK-801 [(+)-5-methyl-10,11-dihydroxy-5H-dibenzo (a,d)-cyclohepten-5,10-imine] dose-dependently induces ipsiversive rotational behavior in the rats with a unilateral striatal lesion produced by transient middle cerebral artery occlusion or in those with a unilateral nigrostriatal lesion produced by 6-hydroxydopamaine. In relation to a functional model of the basal ganglia-thalamocortical 'motor' circuit, the present data suggest that the striatum may be one of the most important sites where MK-801 acts in the basal ganglia, with its being responsible for the circling behavior of the animal models.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8310798     DOI: 10.1007/bf00228583

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  13 in total

1.  Anti-parkinsonian agents are phencyclidine agonists and N-methyl-aspartate antagonists.

Authors:  J W Olney; M T Price; J Labruyere; K S Salles; G Frierdich; M Mueller; E Silverman
Journal:  Eur J Pharmacol       Date:  1987-10-13       Impact factor: 4.432

2.  Morphological characterization of the rat striatal neurons expressing calcineurin immunoreactivity.

Authors:  S Goto; Y Matsukado; E Miyamoto; M Yamada
Journal:  Neuroscience       Date:  1987-07       Impact factor: 3.590

3.  Muscle relaxant action of excitatory amino acid antagonists.

Authors:  L Turski; M Schwarz; W A Turski; T Klockgether; K H Sontag; J F Collins
Journal:  Neurosci Lett       Date:  1985-02-04       Impact factor: 3.046

4.  NMDA antagonists potentiate antiparkinsonian actions of L-dopa in monoamine-depleted rats.

Authors:  T Klockgether; L Turski
Journal:  Ann Neurol       Date:  1990-10       Impact factor: 10.422

5.  Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study.

Authors:  J Kornhuber; J Bormann; M Hübers; K Rusche; P Riederer
Journal:  Eur J Pharmacol       Date:  1991-04-25       Impact factor: 4.432

6.  Factors in amphetamine-induced contralateral rotation in the unilateral 6-OHDA lesion rat model during the first-week postoperative: implications for neuropathology and neural grafting.

Authors:  R J Carey
Journal:  Brain Res       Date:  1992-01-20       Impact factor: 3.252

7.  The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice.

Authors:  M Carlsson; A Carlsson
Journal:  J Neural Transm       Date:  1989       Impact factor: 3.575

8.  Dramatic synergism between MK-801 and clonidine with respect to locomotor stimulatory effect in monoamine-depleted mice.

Authors:  M Carlsson; A Carlsson
Journal:  J Neural Transm       Date:  1989       Impact factor: 3.575

9.  Changes of immunoreactivity for synaptophysin ('protein p38') following a transient cerebral ischemia in the rat striatum.

Authors:  K Korematsu; S Goto; S Nagahiro; Y Ushio
Journal:  Brain Res       Date:  1993-07-09       Impact factor: 3.252

10.  The anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist.

Authors:  E H Wong; J A Kemp; T Priestley; A R Knight; G N Woodruff; L L Iversen
Journal:  Proc Natl Acad Sci U S A       Date:  1986-09       Impact factor: 11.205

View more
  2 in total

Review 1.  Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man.

Authors:  M Gerlach; P Riederer
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

2.  MK-801 inhibits L-DOPA-induced abnormal involuntary movements only at doses that worsen parkinsonism.

Authors:  Melanie A Paquette; Akari M Anderson; Jason R Lewis; Charles K Meshul; Steven W Johnson; S Paul Berger
Journal:  Neuropharmacology       Date:  2010-01-14       Impact factor: 5.250

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.